Literature DB >> 21091932

Diagnosis and management of alcoholic liver disease.

Arthur J McCullough1, Robert S O'Shea, Srinivasan Dasarathy.   

Abstract

Alcohol is the most commonly used hepatotoxin worldwide. About 90% of heavy drinkers (more than 60 g/day of alcohol) show evidence of fatty livers, while only 10-35% develop alcoholic hepatitis and 5-15% developed cirrhosis. The daily intake of alcohol that results in liver injury varies and depends on a number of risk factors. Alcoholic disease developes at lower doses in females, Hispanic, obese objects, and patients with hepatitis C. Insights into the pathogenesis of alcohol-induced liver injury has improved significantly but the translation into clinical benefit has been slow. The importance of continued abstinence and correction of nutritional deficiencies are major components in the long-term management of liver disease. Alcohol hepatitis has a variable mortality and the prognosis is determined most commonly by the modified discriminant function. The mocel of end-stage liver disease (MELD) is being increasingly used to predict outcome in alcoholic hepatitis even though standard cut offs are not available. Anti-inflammatory therapy with corticosteroids and anticytokine therapy with corticosteroids and pentoxifylline are effective for patients with severe alcoholic hepatitis. Patients with endstage liver disease should be considered for liver transplantation. Six months of abstinence is considered to be a requirement prior to transplant, but this length of time may be adjusted in individual bases.
© 2011 The Authors. Journal of Digestive Diseases © 2011 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21091932     DOI: 10.1111/j.1751-2980.2010.00470.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  23 in total

1.  Are People Overoptimistic about the Effects of Heavy Drinking?

Authors:  Frank A Sloan; Lindsey M Eldred; Tong Guo; Yanzhi Xu
Journal:  J Risk Uncertain       Date:  2013-08-01

2.  Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol-related steatohepatitis.

Authors:  Diana Lizarazo; Valerie Zabala; Ming Tong; Lisa Longato; Suzanne M de la Monte
Journal:  J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 4.029

3.  Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin.

Authors:  Ming Tong; Lisa Longato; Teresa Ramirez; Valerie Zabala; Jack R Wands; Suzanne M de la Monte
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

4.  Steroid-Mediated Decrease in Blood Mesenchymal Stem Cells in Liver Transplant could Impact Long-Term Recovery.

Authors:  Nykia D Walker; Yasmine Mourad; Katherine Liu; Michael Buxhoeveden; Catherine Schoenberg; Jean D Eloy; Dorian J Wilson; Lloyd G Brown; Andrei Botea; Faraz Chaudhry; Steven J Greco; Nicholas M Ponzio; Nikolaos Pyrsopoulos; Baburao Koneru; Yuriy Gubenko; Pranela Rameshwar
Journal:  Stem Cell Rev Rep       Date:  2017-10       Impact factor: 5.739

Review 5.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

6.  Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection.

Authors:  Xu Liu; Ayako Hakucho; Jinyao Liu; Tatsuya Fujimiya
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 7.  Zinc deficiency as a mediator of toxic effects of alcohol abuse.

Authors:  Anatoly V Skalny; Margarita G Skalnaya; Andrei R Grabeklis; Anastasia A Skalnaya; Alexey A Tinkov
Journal:  Eur J Nutr       Date:  2017-11-24       Impact factor: 5.614

Review 8.  Pharmacotherapy for alcoholic patients with alcoholic liver disease.

Authors:  Cynthia L Vuittonet; Michael Halse; Lorenzo Leggio; Samuel B Fricchione; Michael Brickley; Carolina L Haass-Koffler; Tonya Tavares; Robert M Swift; George A Kenna
Journal:  Am J Health Syst Pharm       Date:  2014-08-01       Impact factor: 2.637

Review 9.  Alcoholic hepatitis and HCV interactions in the modulation of liver disease.

Authors:  C S Punzalan; T N Bukong; G Szabo
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

10.  Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance?

Authors:  Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.